Winningham Rick E sold $662K of JAZZ
Winningham Rick E sold 2,741 shares of Jazz Pharmaceuticals plc (JAZZ) at $241.57 ($0.66M total) on 2026-05-22.
How this was made
The 30-second read
Why it matters
Insider sales can influence short-term sentiment, but without a fundamental catalyst (earnings, trial, approval, guidance, M&A, or litigation), the trading signal is typically weak.
Market read
Traders may monitor for follow-on disclosures, but this specific filing alone is unlikely to materially change valuation expectations.
What to watch
No 10b5-1 plan is stated, which can increase interpretive noise; however, the article lacks any accompanying narrative about company outlook or risk changes.
Background
The article is an SEC Form 4 insider transaction disclosure for Jazz Pharmaceuticals plc, filed via EDGAR.
Ticker impact
Jazz Pharmaceuticals director Winningham Rick E filed an open-market sale of 2,741 shares at $241.57 on 2026-05-22.
Near-term, expect limited impact; any move is likely sentiment-driven and mean-reverting unless followed by additional news.
The filing is a routine Form 4 open-market sale and explicitly notes no 10b5-1 plan, but the article provides no performance, guidance, or catalyst context.
Market effects
Minimal; insider Form 4 activity generally does not reset sector expectations for biotech/pharma without accompanying clinical/regulatory updates.
None indicated; this is a US-listed issuer insider transaction.
None indicated; no cross-border deal/regulatory event described.
Counterpoint
The sale may reflect diversification, tax planning, or scheduled liquidity needs rather than a negative view on Jazz’s prospects.
Key entities
- issuerJazz Pharmaceuticals plc
Subject of the Form 4 insider transaction; director sold shares open-market.
- insiderWinningham Rick E
Director who sold 2,741 shares at $241.57 on 2026-05-22.
